Molecular Staging Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.
  • Business development

    MSI will build broad usage of the RCAT™ platform and other core technologies through the development of superior diagnostic and genomics tools. To accomplish this, we will pursue vigorous internal development and the establishment of strategic collaborations and licensing agreements to popularize the company’s technology base.

    Amersham Pharmacia Biotech (APB) Partnership
    MSI will make RCAT widely available to the academic community and industrial scientists for research purposes through a strategic partnership with Amersham Pharmacia Biotech. APB is a major international life sciences company with market leadership position in virtually all of the markets in which it competes. APB’s novel systems are used to sequence DNA, uncover the function of genes and proteins, separate biomolecules, screen potential drugs and manufacture biopharmaceuticals. APB will act as MSI’s exclusive distributor for RCAT research reagents.

    Alliances
    We are actively pursuing partnerships in the in vitro diagnostic industry as well as key additional strategic areas. These alliances will enable us to rapidly expand the applications for Rolling Circle Amplification Technology and the other technology platforms at Molecular Staging.

    Financing
    MSI has received financing from Domain Associates, Biotechnology Investments Limited, and Collinson, Howe & Lennox, LLC as well as from Amersham Pharmacia Biotech. For more information,
    please contact:

    Molecular Staging Inc.
    Business Development
    300 George Street
    [email protected]

    Voice (203)772-5000
    FAX (203)776 5276

    Published on October 13, 2012 · Filed under: Uncategorized;
    Comments Off on Business development